Paving the road from bench to bedside in ATMPs

ATMP development can be challenging. Usually, these therapeutic approaches are discovered by researchers at universities or research institutes but in order to develop them as approved ATMPs, further R&D is needed both to generate the science and evidence to support a potential application and also, to be able to manufacture de ATMP under the required standards, in a reproducible and scalable way.

Spain is the worldwide leader in clinical trials in advanced therapy and the science we produce in this field stands out both in quantity and quality. Spain is also the original of the first allogenic stem cell therapy that was approved by the EC in 2018.

In this roundtable, we will discuss about the challenges we face to transform the science and knowledge the Spanish ecosystem has accumulated in the area of cell and gene therapies during the last decades into ATMPs, hereby providing solutions to patients and fostering the development of a competitive ATMP industry creating economic value and employment. We will also have the chance to know about initiatives in other parts of Europe that have fostered the research and manufacturing skill development in order to accelerate the development of the local ATMP ecosystems.

Moderator:

Lidia Cánovas, General Manager, Regulatory Affairs, Asphalion (Spain)

Speakers:

- **Mariano Garcia-Arranz**, RedTerCel (Spain)
- **Darrin Morrissey,** CEO, NIBRT (Ireland)
- **Sol Ruiz,** Biological Products, Advanced Therapies and Biotechnology Division, AEMPS- Spanish Agency of Medicines and Medical Devices (Spain)
- **Pilar Redondo,** Site Head, Takeda (Spain)